Niels Hansen1, Guido Widman2, Svenja Stuff2, Albert J Becker3, Juri-Alexander Witt2, Hojjat Ahmadzadehfar4, Christoph Helmstaedter2, Christian E Elger2. 1. Department of Epileptology, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany. Electronic address: Niels.Hansen@ukb.uni-bonn.de. 2. Department of Epileptology, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany. 3. Department of Neuropathology, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany. 4. Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany.
Abstract
OBJECTIVE: Paraneoplastic limbic encephalitis (LE) occurs frequently with considerable variability according to literature reports. We thus determined the cancer frequency in mixed LE subtypes sharing the diagnosis of temporal lobe epilepsy (TLE). METHODS: All patients underwent magnetic resonance imaging (MRI) of the brain, electroencephalography (EEG) recordings, neuropsychological testing, immunohistochemistry, and clinical examination together with whole body 2-fluor-2-desoxy-d-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) to detect cancer in this observatory study. RESULTS: Ninety-three patients (median: 52 years) with TLE due to autoimmune LE were investigated. Cancer was detected in the FDG-PET/CTs of 3 out of 93 (3.2%) patients with LE. Cancer was diagnosed upon, 5 years earlier and 5 years after FDG-PET/CT in 7 of 93 (7.5%) of all patients with LE. The cancer frequency in those patients was significantly lower than that reported in the largest series of patients with LE associated with and without different antibodies (7.5% vs. 23.5%, Bootstrap test, p < 0.05), but was indistinguishable from the estimated age-dependent cancer frequency in the German regional North-Rhine-Westfalian population without LE in 2014 (Chi-square test: p = 0.2). CONCLUSIONS: Our findings reveal that the cancer frequency in patients with TLE with LE detected by FDG-PET/CT is low and not different from the age-dependent natural cancer occurrence in a regional population.
OBJECTIVE:Paraneoplastic limbic encephalitis (LE) occurs frequently with considerable variability according to literature reports. We thus determined the cancer frequency in mixed LE subtypes sharing the diagnosis of temporal lobe epilepsy (TLE). METHODS: All patients underwent magnetic resonance imaging (MRI) of the brain, electroencephalography (EEG) recordings, neuropsychological testing, immunohistochemistry, and clinical examination together with whole body 2-fluor-2-desoxy-d-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) to detect cancer in this observatory study. RESULTS: Ninety-three patients (median: 52 years) with TLE due to autoimmune LE were investigated. Cancer was detected in the FDG-PET/CTs of 3 out of 93 (3.2%) patients with LE. Cancer was diagnosed upon, 5 years earlier and 5 years after FDG-PET/CT in 7 of 93 (7.5%) of all patients with LE. The cancer frequency in those patients was significantly lower than that reported in the largest series of patients with LE associated with and without different antibodies (7.5% vs. 23.5%, Bootstrap test, p < 0.05), but was indistinguishable from the estimated age-dependent cancer frequency in the German regional North-Rhine-Westfalian population without LE in 2014 (Chi-square test: p = 0.2). CONCLUSIONS: Our findings reveal that the cancer frequency in patients with TLE with LE detected by FDG-PET/CT is low and not different from the age-dependent natural cancer occurrence in a regional population.
Authors: Niels Hansen; Michael Lipp; Jonathan Vogelgsang; Ruth Vukovich; Tristan Zindler; Daniel Luedecke; Stefan Gingele; Berend Malchow; Helge Frieling; Simone Kühn; Johannes Denk; Jürgen Gallinat; Thomas Skripuletz; Nicole Moschny; Jens Fiehler; Christian Riedel; Klaus Wiedemann; Mike P Wattjes; Inga Zerr; Hermann Esselmann; Stefan Bleich; Jens Wiltfang; Alexandra Neyazi Journal: Brain Behav Immun Health Date: 2020-10-01
Authors: Manon Bordonne; Mohammad B Chawki; Matthieu Doyen; Aurelie Kas; Eric Guedj; Louise Tyvaert; Antoine Verger Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-07 Impact factor: 10.057